Elaine M Sloand

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Department of Transfusion Meidcine, Clinical Center, National Instittues of Health, Bethesda, MD 20892, USA
    Blood 104:3782-8. 2004
  2. pmc CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins
    Elaine M Sloand
    National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
    Blood 109:2399-405. 2007
  3. pmc Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients
    Elaine M Sloand
    National Heart Lung and Blood Institute, Hematology Branch, Office of Biostatistics Research, Division of Prevention and Population Sciences, National Institutes of Health, Bethesda, MD 20892 1260, USA
    Exp Hematol 36:1616-24. 2008
  4. ncbi request reprint Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1652, USA
    Blood 100:4427-32. 2002
  5. pmc Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success
    Elaine M Sloand
    Hematology Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Hematol Oncol Clin North Am 24:331-41. 2010
  6. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
  7. doi request reprint Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
    Elaine M Sloand
    National Heart, Lung and Blood Institute, Division of Intramural Research, Hematology Branch, Bethesda, MD 20892, USA
    J Clin Oncol 26:2505-11. 2008
  8. pmc Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:14483-8. 2006
  9. pmc Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Haematologica 94:348-54. 2009
  10. pmc Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 109:3219-24. 2007

Detail Information

Publications34

  1. ncbi request reprint Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Department of Transfusion Meidcine, Clinical Center, National Instittues of Health, Bethesda, MD 20892, USA
    Blood 104:3782-8. 2004
    ..Increased surface CD59 was measured on recipient red cells and granulocytes 1, 3, and 7 days following transfusion in all 6 patients. Our data suggest a potential therapeutic role for GPI-anchored protein transfer for severe PNH...
  2. pmc CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins
    Elaine M Sloand
    National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
    Blood 109:2399-405. 2007
    ..Knock-down of survivin by siRNA resulted in preferential loss of trisomy 8 cells. These results suggest that trisomy 8 cells undergo incomplete apoptosis and are nonetheless capable of colony formation and growth...
  3. pmc Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients
    Elaine M Sloand
    National Heart Lung and Blood Institute, Hematology Branch, Office of Biostatistics Research, Division of Prevention and Population Sciences, National Institutes of Health, Bethesda, MD 20892 1260, USA
    Exp Hematol 36:1616-24. 2008
    ..We hypothesized that suPAR, prevents the interaction of urokinase with membrane-anchored uPAR on residual normal cells...
  4. ncbi request reprint Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1652, USA
    Blood 100:4427-32. 2002
    ..Clinical data demonstrating the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) would favor an active role of the immune system in this syndrome...
  5. pmc Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success
    Elaine M Sloand
    Hematology Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Hematol Oncol Clin North Am 24:331-41. 2010
    ..This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients...
  6. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
    ..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS...
  7. doi request reprint Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
    Elaine M Sloand
    National Heart, Lung and Blood Institute, Division of Intramural Research, Hematology Branch, Bethesda, MD 20892, USA
    J Clin Oncol 26:2505-11. 2008
    ..We evaluated patients with MDS treated with IST at our institution to determine their clinical course compared with a comparable supportive care only group...
  8. pmc Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:14483-8. 2006
    ..The abnormal response of monosomy 7 cells to GCSF would be explained by the expansion of undifferentiated monosomy 7 clones expressing the class IV GCSFR, which is defective in signaling cell maturation...
  9. pmc Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Haematologica 94:348-54. 2009
    ....
  10. pmc Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 109:3219-24. 2007
    ....
  11. ncbi request reprint Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Br J Haematol 123:173-6. 2003
    ..These findings suggest that environmental factors, but not genetic instability of the GPI-AP-deficient clone, foster development or survival of haematopoietic cells with chromosomal abnormalities...
  12. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
    ..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS...
  13. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010
    ....
  14. ncbi request reprint Hematopoietic-specific microRNA expression in human cells
    Shakti H Ramkissoon
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20892, USA
    Leuk Res 30:643-7. 2006
    ..Further our results showed differences in miRNA expression between mouse and human hematopoietic cells, suggesting important regulatory roles of miRNAs in human hematopoiesis and oncogenesis...
  15. pmc Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10, Rm 7C108, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 106:841-51. 2005
    ..An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomy 8 MDS...
  16. pmc Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors
    Matthew J Olnes
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 52:537-41. 2012
    ..However, there are no studies addressing whether repeated administration of G-CSF produces Monosomy 7 aneuploidy in healthy donors...
  17. ncbi request reprint Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, and the Mark O Hatfield Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 47:1250-3. 2007
    ..Even patients who have clinically recovered from aplastic anemia have diminished hematopoietic progenitor cells, so the practicability of PBPC mobilization in these individuals is unknown...
  18. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
    ..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS...
  19. ncbi request reprint Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia
    Jaroslaw P Maciejewski
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 102:3584-6. 2003
    ..Daclizumab appears safe; its efficacy in this pilot protocol suggests that expanded study of this monoclonal antibody in immune-mediated bone marrow failure syndrome is warranted...
  20. ncbi request reprint Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities
    Guibin Chen
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Blood 104:4210-8. 2004
    ..These results imply distinct molecular mechanisms for monosomy 7 and trisomy 8 MDS and implicate specific pathogenic pathways...
  21. ncbi request reprint Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab)
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Intern Med 144:181-5. 2006
    ..Most patients respond to some form of immunosuppressive treatment, but few prospective clinical trials have been performed...
  22. pmc Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, 10 Center Dr, Bldg 10 CRC, Room 3 5140, MSC 1202, Bethesda, MD 20892 1202, USA
    JAMA 304:1358-64. 2010
    ..Variations in telomere length have been reported in severe aplastic anemia but their clinical significance is unknown...
  23. pmc Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes
    Elaine M Sloand
    National Heart, Lung, and Blood Institute NIH, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 16:1665-73. 2010
    ..These findings suggest that in GVHD, inflammation and repeated cell division correlate with the development of karyotypic abnormalities...
  24. doi request reprint Immunosuppressive therapy for myelodysplastic syndromes: refining the indications
    A John Barrett
    Clinical Research Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 3:23-8. 2008
    ..Significantly, long-term follow-up indicates that IST responders have a better progression-free survival than comparable patients with MDS who do not receive IST...
  25. pmc Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
    Agnes S M Yong
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 113:875-82. 2009
    ..Such treatment, as an adjunct to donor lymphocyte infusions and pharmacologic therapy, may reduce the risk of relapse in CML patients who require treatment by SCT...
  26. doi request reprint The role of the immune system in myelodysplasia: implications for therapy
    Elaine M Sloand
    National Heart Lung and Blood Institute, Hematology Branch, Bethesda, MD 20892, USA
    Semin Hematol 45:39-48. 2008
    ..Here, we review the evidence supporting a role of the immune system in the pathophysiology of MDS and the results of clinical trials of immunosuppressive agents...
  27. ncbi request reprint A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome
    Jaroslaw P Maciejewski
    Hematology Branch and Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 117:119-26. 2002
    ..Although anti-TNF therapy with Enbrel was well tolerated at the dosages used in MDS, its efficacy as a single agent appears low...
  28. ncbi request reprint Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
    Jaroslaw P Maciejewski
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 99:3129-35. 2002
    ..Although AA patients with monosomy 7 showed a similar prognosis to those with primary MDS, trisomy 8 in AA appears to have a more favorable prognosis than in MDS...
  29. doi request reprint Hypocellular myelodysplasia
    Elaine M Sloand
    Hematology Branch, National Heart Lung and Blood Institute, 10 Center Drive, Bldg10, CRC Rm 4E5230, Bethesda, MD 20892, USA
    Hematol Oncol Clin North Am 23:347-60. 2009
    ....
  30. doi request reprint Targeting immune dysregulation in myelodysplastic syndromes
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bldg 10 CRC 3 1341, Bethesda, MD 20892, USA
    JAMA 305:814-9. 2011
    ..In this article, we review the pathobiology of immune dysregulation in MDS and summarize the role of immunosuppressive therapy in MDS...
  31. ncbi request reprint Absence of donor-derived keratinocyte stem cells in skin tissues cultured from patients after mobilized peripheral blood hematopoietic stem cell transplantation
    Peiman Hematti
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Hematol 30:943-9. 2002
    ..We investigated the contribution of cells with a primitive hematopoietic phenotype to human epidermal skin formation in recipients of allogeneic mobilized peripheral blood hematopoietic stem cell (HSC) transplantation...
  32. ncbi request reprint Nonisotopic detection of microRNA using digoxigenin labeled RNA probes
    Shakti H Ramkissoon
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Bethesda, MD, USA
    Mol Cell Probes 20:1-4. 2006
    ..The ability to use nonisotopic methods and yet obtain sensitive and reliable results offers an advantage to investigators who prefer to avoid isotopes...
  33. ncbi request reprint Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size
    Gabriela M Baerlocher
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    Exp Hematol 35:1777-81. 2007
    ..To study if telomere length can be used as a surrogate marker for the mitotic history in normal and affected hematopoietic cells from patients with paroxysmal nocturnal hemoglobinuria (PNH)...
  34. doi request reprint Myelodysplastic syndromes: introduction
    Elaine M Sloand
    Semin Hematol 45:1-2. 2008